171 related articles for article (PubMed ID: 7969059)
61. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
62. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
Lee MS; Wang JC; Beran M
J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
[TBL] [Abstract][Full Text] [Related]
63. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
64. [Mechanisms of resistance to DNA topoisomerase II inhibitors].
Kohno K; Takano H; Kuwano M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684
[TBL] [Abstract][Full Text] [Related]
65. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.
Chan VT; Ng SW; Eder JP; Schnipper LE
J Biol Chem; 1993 Jan; 268(3):2160-5. PubMed ID: 8380592
[TBL] [Abstract][Full Text] [Related]
66. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Elsea SH; Hsiung Y; Nitiss JL; Osheroff N
J Biol Chem; 1995 Jan; 270(4):1913-20. PubMed ID: 7829529
[TBL] [Abstract][Full Text] [Related]
67. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
68. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
[TBL] [Abstract][Full Text] [Related]
69. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
[TBL] [Abstract][Full Text] [Related]
70. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
[TBL] [Abstract][Full Text] [Related]
71. The involvement of topoisomerases and DNA polymerase I in the mechanism of induced thermal and radiation resistance in yeast.
Boreham DR; Trivedi A; Weinberger P; Mitchel RE
Radiat Res; 1990 Aug; 123(2):203-12. PubMed ID: 2167497
[TBL] [Abstract][Full Text] [Related]
72. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
[TBL] [Abstract][Full Text] [Related]
73. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
[TBL] [Abstract][Full Text] [Related]
74. Topoisomerase alterations associated with drug resistance in a line of Chinese hamster cells.
Pommier Y; Kerrigan D; Kohn KW
NCI Monogr; 1987; (4):83-7. PubMed ID: 2819737
[No Abstract] [Full Text] [Related]
75. Topoisomerase II as a target of antileukemic drugs.
Zwelling LA; Estey E; Bakic M; Silberman L; Chan D
NCI Monogr; 1987; (4):79-82. PubMed ID: 2819736
[TBL] [Abstract][Full Text] [Related]
76. Divergent patterns of resistance to etoposide and amsacrine.
Spiridonidis CA; Schmotzer JA; Chatterjee S; Berger NA
Trans Assoc Am Physicians; 1986; 99():214-8. PubMed ID: 3603924
[No Abstract] [Full Text] [Related]
77. A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.
Hill BT; Whelan RD; Hosking LK; Shellard SA; Hinds MD; Mayes J; Zwelling LA
Int J Cancer; 1991 Apr; 47(6):899-902. PubMed ID: 1849124
[TBL] [Abstract][Full Text] [Related]
78. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
[TBL] [Abstract][Full Text] [Related]
79. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
80. A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.
Sabourin M; Byl JA; Hannah SE; Nitiss JL; Osheroff N
J Biol Chem; 1998 Oct; 273(44):29086-92. PubMed ID: 9786915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
